1700632483
[1] Cook JR, Hsi ED, Worley S, et al. Immuno histochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, Am J Clin Pathol, 2006, 125(4)
:615-624.
1700632484
1700632485
[2] Greco C, D’A gnano I, Vitelli G, et al. c2MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF2BB. Int J Immunopathol Pharmacol, 2006, 19(1)
:67-79.
1700632486
1700632487
[3] 张之南，沈悌．血液病诊断及疗效标准（第3版）．北京：科学出版社，2007
:232-235.
1700632488
1700632489
[4] 张之南，杨天楹，郝玉书．血液病学．北京：人民卫生出版社，2003
:1341-1359.
1700632490
1700632491
[5] 侯建，傅卫军．多发性骨髓瘤及其相关疾病．上海：上海科学技术出版社，2002
:90-102.
1700632492
1700632493
[6] 陈灏珠．实用内科学（第12版）．北京：人民卫生出版社，2005
:2410-2414.
1700632494
1700632495
[7] Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria formultiple myeloma. Leukemia, 2006, 20(9)
:1467-1473.
1700632496
1700632497
[8] Badogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood, 2004, 103(1)
:20-32.
1700632498
1700632499
[9] Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of CD56 dim natural killer cell subset in patients with cancer. Eur J Immunol, 2003, 33(l)
:119-124.
1700632500
1700632501
[10] Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96(9)
:2943-2950.
1700632502
1700632503
[11] Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med, 2006, 354(10)
:1076-1078.
1700632504
1700632505
[12] Richardsonp G, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100(9)
:3063-3067.
1700632506
1700632507
[13] Musto P, Falcome A, Sanpaolo G, et al. Bortezomib for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res, 2006, 30(3)
:283-285.
1700632508
1700632509
[14] Hussein MA, Saleh M, Ravandi F, et al. Phase 2 study of arsenic trioxide in patients with releapsed or refractroy multiple myeloma. Br J Haematol, 2004, 125(4)
:470-476.
1700632510
1700632511
[15] Le Gouill S, Pellat Decaungnck C, Harousseau JL, et al. Farnesyltransferase inhibitor R1157777 induces apoptosis of human myeloma cells. Leukemia, 2002, 16(9)
:1664-1667.
1700632512
1700632513
[16] Harrison SJ, Cook G, Nibbs RJ, et al. Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Rev Anticancer Ther, 2006, 6(12)
:1769-1785.
1700632514
1700632515
[17] Crawler C, Lalancette M, Szydlo R, et al. Outcomes of reduces-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood, 2005, 105(11)
:4532-4553.
1700632516
1700632517
[18] Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybirdization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. Blood. 2004, 103(11)
:4056-4061.
1700632518
1700632519
[19] Bellucci R, Ritz J. Allogeneic stem cell transplantation for multiple myeloma. Rev Clin Exp Hematol, 2002, 6(3)
:205-224.
1700632520
1700632521
[20] Nakashima Y, Shirat Suchi M, Abe Y, et al. Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma. Leuk Lymphoma, 2005, 46(8)
:1217-1222.
1700632522
1700632523
[21] Smith A, Wisloff F, Sam Son D, et al. Guidelines on the diagnosis and management of multiple myeloma, 2005. Br J Haematol, 2006, 132(4)
:410-451.
1700632524
1700632525
（蔡 真）
1700632526
1700632527
1700632528
1700632529
1700632531
内科学新进展 第五章 内分泌疾病
1700632532
[
上一页 ]
[ :1.700632483e+09 ]
[
下一页 ]